- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02061189
Pilot Study of an Innovative Physiotherapy in Patients With Infantile Spinal Muscular Atrophy (SMA) (ExerASI)
Physical Exercise and Neuromuscular Diseases: Pilot Study of an Innovative Physiotherapy in Patients With Infantile Spinal Muscular Atrophy
This clinical trial aims to test a new physio-therapeutic approach tailored to type 2 and 3 Spinal Muscular Atrophy patients, based on physical training in swimming-pool. This specific exercise should promote motor skills of trained patients, as we have observed in different mouse models. Patient's motor skills will be assessed using different scales including MFM and Hammersmith.
This clinical trial attempts to develop a new non-invasive motor scale with sophisticated instruments.
This scale will be useful in future clinical trials on SMA, given the lack of sensitivity of currently available scales.
In addition, the study attempts to validate a questionnaire on post-exercise physical well-being.
Study Overview
Status
Intervention / Treatment
Detailed Description
This multicenter study is based on a longitudinal assessment of the natural disease progression and on the effects of exercise protocol in a swimming pool. This study will compare patients to themselves after determining motor skills and the disease natural course for 12 months.
The study will compare different scales (MFM, Hammersmith) to our new innovative scale based on non-invasive analysis of motor skills.
30 patients will be enrolled and tested with MFM, Hammersmith and our non-invasive scale every 6 months for a total of 18 to 36 months due to the slow natural progression of the disease.
Among these 30 patients, 10 patients will be selected to perform a 6 months training in a swimming pool, from 12 to 18 months or 18 to 24 months or 24 to 30 months after enrollment, in defined and reproducible conditions.
These trained patients will finally be reassessed at 18 and 24 months or 24 and 30 months or 30 and 36 months to test the therapeutic effect of the training compared to the slope of the natural disease progression, and other parameters.
Only patients who have undergone training in the swimming pool will be reevaluated at 24 or 30 or 36 months (6 months post-training) to assess long term exercise effects.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hauts-de-Seine
-
Garches, Hauts-de-Seine, France, 92380
- Raymond Poincaré Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with type II SMA who can sustain a sitting position without orthopedic corset or type III SMA, with genetic confirmation of the disease.
- Age from 5 to 10 years old.
- Patient able to understand and execute training instructions, and perform predetermined movements.
- Patient able to achieve physical exercises in a swimming pool.
- MFM score > 35.
- Patient having any contraindication to physical rehabilitation in a swimming pool.
- Consent signed by the holders of parental responsibility for children participating in the study.
- Patient with social security insurance.
Exclusion Criteria:
- Pneumonia: the inclusion is to be delayed for at least 3 months after recovery of infection.
- Heart, renal or hepatic failure.
- Patient undergoing a major surgery during the study: spinal fusion.
- Patient under the care of a guardian.
- Inability to cooperate.
- Medication potentially interfering with the SMA (i.e., riluzole, salbutamol, phenylbutyrate, sodium valproate) started less than 6 months before inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Swimming pool training group
10 patients will be selected to perform a 6 months training in a swimming pool, from M12 to M18 or M18 to M24 or M24 to M36, in defined and reproducible conditions.
|
10 patients will undergo a training program of physical exercise in a swimming pool, 3 days per week during 6 months.
Each session will last for 20 minutes.
|
NO_INTERVENTION: Control group
20 patients with same assessments at M0, M6, M12 and M18, but:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motor function measurement (MFM)
Time Frame: 18 months (control group) to 36 months maximum (swimming pool group)
|
The motor ability of all patients will be followed for 18 or 24 months, for a total of four or five functional assessments, 1 every 6 months.
Each patient will be assessed with the MFM.
|
18 months (control group) to 36 months maximum (swimming pool group)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hammersmith scale
Time Frame: M18 or M24 or M30 or M36
|
Motor Assessments will be performed in the same order : MFM first, then Hammersmith scale.
|
M18 or M24 or M30 or M36
|
Questionnaire on post-exercise physical well-being
Time Frame: M18 or M24 or M30 or M36
|
Force and pain felt assessment by questionnaire just before and after each physical training session for 6 months.
|
M18 or M24 or M30 or M36
|
Non invasive motor capacity assessment
Time Frame: M18 or M24 or M30 or M36
|
Monitoring motor capacity with a non-invasive sophisticated instrument operating in the Paris Descartes University platform.
This monitoring will be performed for 18 or 24 months, for a total of four or five functional assessments, 1 every 6 months.
|
M18 or M24 or M30 or M36
|
Collaborators and Investigators
Investigators
- Principal Investigator: Susana QUIJANO-ROY, MD, PhD, Raymond Poincaré Hospital, Garches, FRANCE
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Spinal Cord Diseases
- Heredodegenerative Disorders, Nervous System
- Motor Neuron Disease
- Muscular Atrophy
- Atrophy
- Muscular Atrophy, Spinal
- Neuromuscular Diseases
- Spinal Muscular Atrophies of Childhood
Other Study ID Numbers
- P120124
- 2013-A01331-44 (OTHER: IDRCB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infantile Spinal Muscular Atrophy of Type 2 or 3
-
Scholar Rock, Inc.CompletedNeuromuscular Diseases | Neuromuscular Manifestations | Atrophy | Muscular Atrophy | Spinal Muscular Atrophy | Muscular Atrophy, Spinal | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type 2United States, Spain, Italy, Netherlands
-
Scholar Rock, Inc.Active, not recruitingNeuromuscular Diseases | Neuromuscular Manifestations | Atrophy | Muscular Atrophy | Spinal Muscular Atrophy | Muscular Atrophy, Spinal | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type 2 | Anti-myostatinUnited States, Germany, Belgium, Spain, United Kingdom, Netherlands, France, Italy, Poland
-
Tehran University of Medical SciencesUnknownInfantile Spinal Muscular Atrophy, Type I [Werdnig- Hoffman]Iran, Islamic Republic of
-
Institut de Myologie, FranceInstitut RocheCompletedType 2 Spinal Muscular Atrophy | Type 3 Spinal Muscular AtrophyBelgium, France, Germany
-
Marco CapogrossoRoche-GenentechNot yet recruitingSpinal Muscular Atrophy | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy 4United States
-
Istanbul Medipol University HospitalIstanbul UniversityRecruitingNeuromuscular Diseases | Spinal Muscular Atrophy Type 3Turkey
-
Washington University School of MedicineActive, not recruitingSpinal Muscular Atrophy | Spinal Muscular Atrophy Type 3 | Spinal Muscular Atrophy Type IIUnited States, Canada
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Scholar Rock, Inc.Active, not recruitingNeuromuscular Diseases | Neuromuscular Manifestations | Atrophy | Muscular Atrophy | Spinal Muscular Atrophy | Muscular Atrophy, Spinal | Spinal Muscular Atrophy Type 3 | SMA | Anti-myostatin | Spinal Muscular Atrophy Type IIUnited States, Spain, Belgium, Germany, Netherlands, Poland, Italy, France, United Kingdom
-
Marco CapogrossoRoche-GenentechRecruitingSpinal Muscular Atrophy Type 3 | Spinal Muscular Atrophy Type 4United States
Clinical Trials on Physical exercise in a swimming pool during 6 months
-
Universidad de GranadaHospital Clinico Universitario San Cecilio; Centro de Investigación Biomédica; Instituto Mixto Universitario Deporte y Salud and other collaboratorsCompletedObesity | Overweight | Mental Health Wellness 1 | Cognitive Function 1, Social
-
Somerville Office of Emergency ManagementCompletedHemorrhageUnited States
-
University Hospital TuebingenRecruitingSarcoma | Head and Neck Cancer | Pancreas Cancer | Esophageal Carcinoma | Cervix Uteri Cancer | Bronchial Carcinoma | Tumor of the BrainGermany
-
University Hospital TuebingenRecruiting
-
Cliniques universitaires Saint-Luc- Université...CompletedCritical IllnessBelgium
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
University College, LondonNational Institute for Health Research, United KingdomRecruitingHead and Neck FibrosisUnited Kingdom
-
Centre Hospitalier Metropole SavoieCompletedDiet Habit | Type I Diabetes | Activity, Motor | ControlFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
University Hospital, Strasbourg, FranceUnknownSigns and Symptoms, RespiratoryFrance